New Antibody Cocktail for Treating Cobra Bites

31 Oct 2026

Tags: Social Justice   Social Services   Health sector issues

Source: The Indian Express

New Antivenom: Key Findings

• Research institutions: Scientists from the Centre for Ecological Sciences (CES), Indian Institute of Science (IISc), Bengaluru, and the Technical University of Denmark (DTU) have developed an experimental antibody cocktail targeting venom from multiple cobra species. The findings were published in Science Translational Medicine.
• Experimental results: The antibody cocktail protected mice injected with venom from spectacled cobras, monocled cobras and two king cobra species. It remained effective even when administered 30 minutes after venom injection.
• Key innovation: The study demonstrated that carefully selected and engineered antibodies could neutralise venom using relatively small quantities, potentially reducing treatment costs and safety concerns associated with high antibody doses.
• Future potential: The approach could help develop broader-spectrum antivenoms against diverse snake species worldwide, subject to further research and clinical validation.

Why Is Snakebite Treatment Challenging in India?

• Public health burden: Government data cited in the report estimated approximately 50,000 snakebite deaths annually in India (2024). The spectacled cobra (Naja naja) reportedly accounts for at least 12.5% of these deaths, potentially an underestimate because the snake is not always identified.
• Neurotoxic venom: Cobras primarily use neurotoxins that disrupt nerve signalling, causing paralysis and potentially respiratory failure. Cardiac complications and other effects may also occur.
• Venom variability: Different cobra species possess different venom compositions, while venom from the same species may vary geographically, limiting the effectiveness of a single antivenom formulation.
• Limitations of existing antivenom: India’s conventional polyvalent antivenom targets the Big Four venomous snakes but does not effectively neutralise king cobra venom.
• Healthcare access: Delayed transport to healthcare facilities and inadequate availability of appropriate antivenoms in some centres increase the risk of death.

How Does the New Antibody Cocktail Work?

• Antibody generation: Researchers exposed animals such as alpacas and llamas to snake venom, allowing them to develop antibodies. The antibodies were then extracted and selected for their ability to neutralise venom toxins.
• Antibody cocktail: Antibodies targeting venom components from different cobra species were combined to produce a broader-spectrum experimental treatment.
• Advantages: Carefully selected antibodies may neutralise toxins more efficiently, potentially reducing the quantity required compared with earlier experimental antibody-based approaches.
• Current limitation: The findings are based on animal experiments. The cocktail is not yet an established treatment for human snakebite, and further studies are needed to establish its safety, efficacy, dosage and clinical applicability.

India’s Big Four Venomous Snakes

• Spectacled cobra (Naja naja): Neurotoxic venom; found widely across India.
• Common krait (Bungarus caeruleus): Neurotoxic venom that can cause severe paralysis.
• Russell’s viper (Daboia russelii): Primarily haemotoxic and procoagulant effects, potentially causing severe bleeding and kidney injury.
• Saw-scaled viper (Echis carinatus): Haemotoxic venom that can cause blood-clotting abnormalities and bleeding.

Significance for UPSC

• Biotechnology: Demonstrates the application of antibody engineering and toxin-neutralisation research in developing next-generation biologics.
• Public health: Could improve snakebite treatment, particularly in rural and underserved regions where snakebite mortality remains high.
• One Health relevance: Snakebite prevention and treatment require coordination across human healthcare, ecological research, venom surveillance and health-system preparedness.
• Way forward: India needs improved access to antivenoms, rapid referral systems, better identification of snake species and continued research into region-specific and broader-spectrum treatments.

Conclusion: The experimental antibody cocktail offers a promising alternative to conventional antivenoms by targeting venom from multiple cobra species with potentially smaller antibody doses. Its eventual public-health impact will depend on successful clinical trials, affordable production and reliable access to treatment.